Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022
November 22 2022 - 07:05AM
GlobeNewswire Inc.
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company revolutionizing the delivery of therapies to the back of
the eye through the suprachoroidal space (SCS®), announced today
that management will participate in the following conferences in
November and December 2022:
BTIG Ophthalmology DayFireside ChatTuesday,
November 29, 2022 at 10:30 a.m. ET
Piper Sandler 34th Annual Healthcare
ConferenceCorporate PresentationThursday, December 1, 2022
at 9:50 a.m. ET
Ophthalmology Innovation Summit (OIS) XIIPanel
Discussion: Spotlight on Gene & Cell TherapyRetina Innovation
Showcase: Corporate PresentationSaturday, December 3, 2022
Cantor Medical & Aesthetic Dermatology,
Ophthalmology & MedTech ConferenceOphthalmology Panel
Discussion: Take A Look At What's In Store For Wet AMD &
Related Diabetic Eye DiseasesThursday, December 8, 2022 at 2:45
p.m. ET
A link to the live and archived webcasts may be
accessed on the Clearside website under the Investors section:
Events and Presentations.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company revolutionizing the delivery of therapies
to the back of the eye through the suprachoroidal space (SCS®).
Clearside’s SCS injection platform, utilizing the Company’s
proprietary SCS Microinjector®, enables an in-office, repeatable,
non-surgical procedure for the targeted and compartmentalized
delivery of a wide variety of therapies to the macula, retina or
choroid to potentially preserve and improve vision in patients with
sight-threatening eye diseases. Clearside is developing its own
pipeline of small molecule product candidates for administration
via its SCS Microinjector and strategically partners its SCS
injection platform with companies utilizing other ophthalmic
therapeutic innovations. Clearside’s first product, XIPERE®
(triamcinolone acetonide injectable suspension) for suprachoroidal
use, is commercially available in the U.S. For more information,
please visit www.clearsidebio.com.
Investor and Media Contacts:Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Mar 2023 to Mar 2023
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Mar 2022 to Mar 2023